ZTS logo

Zoetis Inc. Class A (ZTS)

$83.48

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ZTS

Market cap

$33.92B

EPS

5.88

P/E ratio

12.3

Price to sales

3.25

Dividend yield

2.54%

Beta

0.673243

Price on ZTS

Previous close

$84.39

Today's open

$84.05

Day's range

$83.05 - $85.56

52 week range

$68.77 - $132.49

Profile about ZTS

CEO

Kristin C. Peck

Employees

14500

Headquarters

Parsippany, NJ

Exchange

New York Stock Exchange

Shares outstanding

406316147

Issue type

Common Stock

ZTS industries and sectors

Healthcare

Pharmaceuticals

News on ZTS

Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Nov 16, 2026

news preview

Top 50 High-Quality Dividend Growth Stocks For November 2026

I track 50 high-quality dividend growth stocks to identify favorable entry points, prioritizing long-term total return alongside a growing dividend stream. Forty stocks offer estimated future returns of at least 10%; 27 appear undervalued relative to historical free cash flow. ResMed leads with 41.60% estimated return potential; MarketAxess rose to fifth at 28.50% after a valuation upgrade and higher fair value estimate.

news source

Seeking Alpha • Nov 14, 2026

news preview

Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief

ZTS' Cytopoint Plus secures a USDA license, offering dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections.

news source

Zacks Investment Research • Nov 12, 2026

news preview

SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For November 2026

The 4-Factor Dividend Growth Strategy targets quality and total return, outperforming SCHD with a 14.98% average return versus SCHD's 14.31%. I select stocks based on free cash flow to debt, 5-year dividend growth, return on capital employed, and forward yield, emphasizing growth and quality. Recent SCHD outperformance has narrowed the gap, but my strategy has regained momentum since September 2026.

news source

Seeking Alpha • Nov 12, 2026

news preview

Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Cytopoint Plus is the first and only USDA-licensed next-generation mAb that provides 75 days of allergic itch relief in a single injection.

news source

Business Wire • Nov 11, 2026

news preview

Zoetis to Participate in the Jefferies Global Healthcare Conference in London

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 2 p.m. GMT. Interested parties can access the live webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event.

news source

Business Wire • Nov 10, 2026

news preview

ZTS Q3 Earnings Call Highlights Competitive Pressures and Outlook

Zoetis beats Q3 earnings estimates despite revenue weakness, as competitive pressures, targeted promotions and product innovation shape its cautious 2027 outlook.

news source

Zacks Investment Research • Nov 9, 2026

news preview

What Zoetis (ZTS) Said on Its Q3 Earnings Call

Zoetis NYSE: ZTS reported lower third-quarter revenue as competition and weaker veterinary visits pressured its companion animal business, while livestock and diagnostics provided growth. The animal health company narrowed its full-year revenue outlook to the high end of its previous range and raised its adjusted earnings guidance.

news source

MarketBeat • Nov 8, 2026

news preview

Zoetis Inc. (ZTS) Q3 2026 Earnings Call Transcript

Zoetis Inc. ( ZTS ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Mathieu Aussermeier Kristin Peck - CEO & Director James Saccaro - Executive VP, CFO & COO Conference Call Participants Christopher Schott - JPMorgan Chase & Co, Research Division David Westenberg - Piper Sandler & Co., Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Erin Wilson Wright - Morgan Stanley, Research Division Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Navann Ty Dietschi - BNP Paribas, Research Division Christopher LoBianco - TD Cowen, Research Division Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division Steven Dechert - KeyBanc Capital Markets Inc., Research Division Presentation Operator Welcome to the third quarter 2026 financial results conference call and webcast for Zoetis.

news source

Seeking Alpha • Nov 6, 2026

news preview

Zoetis: Quality Company Trading Cheap

Zoetis Inc., formerly Pfizer's veterinary arm, is a global leader in animal pharmaceuticals and diagnostics. ZTS generates most revenue from companion animal products, with approximately 30% from livestock healthcare solutions. We review why the stock has done so poorly and tell you why we went long.

news source

Seeking Alpha • Nov 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Zoetis Inc. Class A

Open an M1 investment account to buy and sell Zoetis Inc. Class A commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ZTS on M1